Mass spectrometry quantifies target engagement for a KRASG12C inhibitor in FFPE tumor tissue

Quantifying KRAS G12C Covalent Drug Inhibitor Activity in Mouse Tumors Using Mass Spectrometry

(2023) John C. Tran et al.   Analytical Chemistry

An Introduction to Mass Spectrometry-Based Proteomics

(2023) Steven R. Shuken   Journal of Proteome Research

The path to the clinic: a comprehensive review on direct KRASG12C inhibitors

(2022) Albert K. Kwan et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Discovery of AZD4625, a Covalent Allosteric Inhibitor of the Mutant GTPase KRASG12C

(2022) Jason G. Kettle et al.   JOURNAL OF MEDICINAL CHEMISTRY

Accelerating the Validation of Endogenous On-Target Engagement and In Cellulo Kinetic Assessment for Covalent Inhibitors of KRASG12C in Early Drug Discovery

(2022) Vasudev Kantae et al.   ACS Chemical Biology

AZD4625 is a potent and selective inhibitor of KRAS G12C

(2022) Atanu Chakraborty et al.   MOLECULAR CANCER THERAPEUTICS

The addition of FAIMS increases targeted proteomics sensitivity from FFPE tumor biopsies

(2022) Steve Sweet et al.   Scientific Reports

Assessment of KRAS G12C Target Engagement by a Covalent Inhibitor in Tumor Biopsies Using an Ultra-Sensitive Immunoaffinity 2D-LC–MS/MS Approach

(2022) Lingyao Meng et al.   ANALYTICAL CHEMISTRY

Distribution of KRASG12C Somatic Mutations across Race, Sex, and Cancer Type

(2021) Amin H. Nassar et al.   NEW ENGLAND JOURNAL OF MEDICINE

Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer

(2020) Jay B. Fell et al.   JOURNAL OF MEDICINAL CHEMISTRY

Recent advances in mass spectrometry based clinical proteomics: applications to cancer research

(2020) Andrew Macklin et al.   Clinical Proteomics

KRASG12C inhibitor: combing for combination

(2020) Atanu Chakraborty   BIOCHEMICAL SOCIETY TRANSACTIONS

Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor

(2018) Matthew R. Janes et al.   CELL

Targeted data-independent acquisition for mass spectrometric detection of RAS mutations in formalin-fixed, paraffin-embedded tumor biopsies

(2018) Yeoun Jin Kim et al.   Journal of Proteomics

Precise characterization of KRAS4b proteoforms in human colorectal cells and tumors reveals mutation/modification cross-talk

(2018) Ioanna Ntai et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

An Internally Controlled Quantitative Target Occupancy Assay for Covalent Inhibitors

(2018) Rasmus Hansen et al.   Scientific Reports

What is targeted proteomics? A concise revision of targeted acquisition and targeted data analysis in mass spectrometry

(2017) Eva Borràs et al.   PROTEOMICS

Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State

(2016) M. P. Patricelli et al.   Cancer Discovery

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

(2013) Jonathan M. Ostrem et al.   NATURE